SCOBUREN INJ. 20MG/ML

Indications

• Motion sickness
• Nausea and vomiting
• Postoperative nausea and vomiting
• Vertigo

Dosage

Children: Refer to established clinical guidelines for specific dosing recommendations, as no specific doses are provided.

Adults: Refer to established clinical guidelines for specific dosing recommendations, as no specific doses are provided.

Mechanism of action

Butylbromide acts as a competitive antagonist of muscarinic acetylcholine receptors. By inhibiting the binding of acetylcholine, it decreases the excitability of the vestibular nuclei and the vomiting center, leading to a reduction in the symptoms of motion sickness and other nausea-inducing stimuli.

Pharmacodynamics

The pharmacodynamic effects of butylbromide include the reduction of secretions in the respiratory tract, bronchodilation, and decreased gastrointestinal motility. These effects are mediated through the blockade of muscarinic receptors, which are linked to parasympathetic nervous system activity. The onset of action is typically within 30 minutes, and the duration of effects can vary based on the formulation and dosage.

Pharmacokinetics

Butylbromide is absorbed through the gastrointestinal tract and exhibits high bioavailability. It is metabolized in the liver via cytochrome P450 enzymes, producing various metabolites. The drug has a half-life that allows for once or twice daily dosing, but specific pharmacokinetic parameters such as clearance and volume of distribution are not well-documented. Renal excretion is the primary route of elimination for the metabolites.

Contra-indications

• Hypersensitivity to butylbromide or any of its components
• Glaucoma
• Prostatic hypertrophy
• Myasthenia gravis

Adverse effects

• Dry mouth
• Constipation
• Blurred vision
• Dizziness
• Urinary retention
• Nausea

Interactions

• Anticholinergic agents
• Antidepressants (particularly tricyclics)
• Antihistamines
• Muscle relaxants
• Alcohol (can enhance sedative effects)

Precautions

• Use with caution in elderly patients
• May impair ability to drive or operate machinery
• Monitor for signs of urinary retention
• Use in patients with a history of cardiovascular disease with caution

Pregnancy

The safety of butylbromide during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether butylbromide is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Oral tablets
• Syrup
• Injectable solution

Indications

• Motion sickness
• Pre-operative sedation
• Nausea and vomiting associated with various conditions
• Palliative care for severe nausea

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Hyoscine exerts its effects by competitively inhibiting the action of acetylcholine at muscarinic receptors in the central and peripheral nervous systems. This blockade results in decreased parasympathetic nervous system activity, leading to effects such as reduced gastrointestinal motility and secretion, as well as central nervous system effects that can include sedation and reduced motion sickness symptoms.

Pharmacodynamics

The primary pharmacodynamic effects of hyoscine include its antinausea, antiemetic, and sedative properties. By blocking muscarinic receptors, hyoscine decreases the activity of the vestibular system, which is involved in balance and motion perception, thus alleviating symptoms of motion sickness. Additionally, it can cause sedation and drowsiness, making it useful for pre-operative sedation.

Pharmacokinetics

Hyoscine is well absorbed from the gastrointestinal tract and can also be administered transdermally or via injection. It has a rapid onset of action, typically within 30 minutes when administered orally or intramuscularly. The drug is metabolized primarily in the liver and has a relatively short half-life, necessitating multiple doses for sustained effect. It crosses the blood-brain barrier, contributing to its central nervous system effects. The elimination half-life ranges from 3 to 12 hours, and it is excreted mainly in the urine.

Contra-indications

• Hypersensitivity to hyoscine or any of its components
• Angle-closure glaucoma
• Myasthenia gravis
• Severe ulcerative colitis
• Tachycardia
• Prostatic hypertrophy

Adverse effects

• Dry mouth
• Dizziness
• Blurred vision
• Constipation
• Urinary retention
• Tachycardia
• Confusion, especially in elderly patients
• Nausea

Interactions

• Anticholinergic drugs may enhance the effects of hyoscine
• Potentiate the effects of other CNS depressants, such as alcohol, benzodiazepines, and opioids
• May reduce the efficacy of prokinetic agents

Precautions

• Use with caution in patients with hepatic or renal impairment
• Careful monitoring in elderly patients due to increased sensitivity to anticholinergic effects
• Avoid use in patients with a history of arrhythmias
• Use with caution in patients with cardiovascular disease

Pregnancy

Hyoscine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Consult relevant guidelines.

Breast-feeding

Hyoscine is excreted in breast milk; caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Tablets
• Injection
• Transdermal patches
• Syrup